Détails de séances
mardi 29 mai
Les séances seront présentées dans la langue de leur titre.
16 h à 17 h 30
The risk of HPV infection decreases with age, however a large portion of mid-adult women remains at risk. Epidemiologic studies have reported a second peak of HPV infection in older women. In Canada, HPV vaccination programs have already demonstrated impact and effectiveness in younger age groups. Clinical trials with HPV vaccines demonstrated high efficacy, immunogenicity, and acceptable safety in women aged 24–45 years, regardless of previous exposure to HPV vaccine type. Recently published data also support the efficacy of HPV vaccination in susceptible women and in preventing recurrent disease in women treated for high-grade cervical lesions which represent a large burden. This data may help policy makers to consider vaccination of mid-adult women.
mercredi 30 mai
9 h à 10 h 30
Influenza vaccines are about half as effective for adults over 65 as they are for adults under 65. With the availability of the high-dose influenza vaccine in Canada as of 2015, NACI has performed a comprehensive literature review of the high-dose and adjuvanted influenza vaccine, the output of which has been used to inform NACI’s 2018/2019 seasonal influenza vaccine statement, which now recommends that the high-dose be offered to individuals over the standard-dose vaccine for adults over 65. This session will review how NACI evaluates the evidence for these vaccines, provide highlights from the NACI Literature Review and NACI recommendations and provide a rationale for the updated recommendations. Finally, this session will provide an overview of the experiences using the high-dose influenza vaccine and offer a path forward on its utility to reduce the burden of influenza among seniors in Canada.
11 h 15 à 12 h 15
- Efficacy and Effectiveness of High-Dose versus Standard-Dose Influenza Vaccination for Older Adults: A Systematic Review and Meta-analysis
- The Predicted Public Health Impact of HZ/su in Canadian Adults ≥50 Years of Age
- Community-led Delivery of Influenza Vaccinations Amongst Métis Albertans
13 h 30 à 15 h 15
- Public health benefit of pediatric pneumococcal conjugate vaccine (PCV) immunization programs in children <5 years
- Mobilisation des parties prenantes et planification de la mise en œuvre d’un programme provincial d’entretien motivationnel sur l’immunisation dans les maternités
- Measles immunization coverage in Saskatchewan – what barriers are there to achieving herd immunity threshold (92 – 95% coverage)?
- Increasing public confidence in vaccines - barriers and opportunities from a policy perspective
- Building Digital Connections: Three Years of Mobile App Immunization Reporting with CANImmunize and Ottawa Public Health
Letting kids lead improvements in the delivery of vaccinations at school: Introducing The CARD™ System
15 h 30 à 16 h 15
School based vaccination programs are an efficient strategy for delivering vaccinations to adolescents. Despite their effectiveness, they are associated with a negative experience for many students due to the pain from injection. Concerns about pain can induce fear, which increases pain perception and fainting risk. Students can develop needle fears which reduce compliance with vaccinations and other health care interventions in the future.
The objectives of this presentation is to describe the importance of pain as a quality indicator of school vaccination programs and review evidence-based strategies for mitigating pain. The results of a CIHR-funded pilot study will be shared to develop and implement a multifaceted knowledge translation (KT) intervention into the school vaccination program to improve the vaccination experience. The key KT tools and policies developed to support practice changes will be presented to facilitate discussion and broader uptake.
- Anna Taddio, Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
- Leslie Alderman, Vaccine Preventable Disease Nurse, Niagara Region Public Health